Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Intercept Pharmaceuticals (NQ: ICPT )

10.48 -0.32 (-2.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,313,031
Open 10.73
Bid (Size) 10.00 (21)
Ask (Size) 10.67 (5)
Prev. Close 10.80
Today's Range 9.850 - 10.74
52wk Range 8.822 - 21.86
Shares Outstanding 41,782,727
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions. 
Via Benzinga
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... 
Via Benzinga

Performance

YTD
-16.36%
-16.36%
1 Month
+1.85%
+1.85%
3 Month
-10.73%
-10.73%
6 Month
-22.14%
-22.14%
1 Year
-31.23%
-31.23%

More News

Read More
Why CymaBay Therapeutics Stock Is Jumping Today
Via The Motley Fool
Analyst Ratings for Intercept Pharma
Via Benzinga
Expert Ratings for Intercept Pharma
Via Benzinga
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
Via The Motley Fool
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
Via Investor's Business Daily
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2023
Via Benzinga
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
Via Benzinga
Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug
Via Investor's Business Daily
FDA Strikes Out Intercept Pharma's Obeticholic Acid Application For NASH Patients, Focus Shifts To Rare Liver Diseases
Via Benzinga
New Data Shows Intercept's Fixed Dose Obeticholic Acid Combo Normalize Multiple Biomarkers In Liver Disease
Via Benzinga
Top 5 Health Care Stocks That Could Blast Off In May
Via Benzinga
The Rising Challenge for Intercept Pharmaceuticals: Analyst Downgrade Amid Ocaliva's DILI Concerns
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2023
Via Benzinga
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
Via Benzinga
Dow Tumbles 100 Points; Micron Technology Shares Plunge
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Rises Over 50 Points; Greenhill Shares Spike Higher
Via Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
Via Benzinga
Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug
Via Investor's Business Daily
US Stocks Mixed; Nordic American Tankers Posts Upbeat Results
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.